Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Koerber

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|July 15, 2011
Dalteparin in critically ill patientsMaureen A Smythe, John M Koerber
Chest|January 18, 2002
The heparin anti-Xa therapeutic range: are we there yet?Maureen A Smythe, Joan C Mattson, John M Koerber
Chest|April 3, 2007
The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospitalMaureen A Smythe, John M Koerber, Joan C Mattson
Chest|May 21, 2008
The financial impact of heparin-induced thrombocytopeniaMaureen A Smythe, John M Koerber, Maureen Fitzgerald, et al.
The Annals of Pharmacotherapy|August 29, 2014
Implications of heparin-induced thrombocytopenia overdiagnosisMaureen A Smythe, John M Koerber, Lisa L Forsyth, et al.
The Annals of Pharmacotherapy|December 14, 2004
Effect of lepirudin on the international normalized ratioJennifer L Stephens, John M Koerber, Joan C Mattson, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
A comparison of lepirudin and argatroban outcomesMaureen A Smythe, Jennifer L Stephens, John M Koerber, et al.
Hospital Pharmacy|March 7, 2024
Hospital Acquired Venous Thromboembolism: A Preventability AssessmentMaureen A Smythe, John M Koerber, Amanda Roberts, et al.
Hospital Practice (1995)|July 31, 2018
Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomesSarah Eisho, Nouran M Salem, Janet L Hoffman, et al.
The Annals of Pharmacotherapy|May 30, 2003
Comparing methods of establishing the aPTT therapeutic range of heparinClaire I Liepman, John M Koerber, Joan C Mattson, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|July 15, 2011
Dalteparin in critically ill patientsMaureen A Smythe, John M Koerber
Chest|January 18, 2002
The heparin anti-Xa therapeutic range: are we there yet?Maureen A Smythe, Joan C Mattson, John M Koerber
Chest|April 3, 2007
The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospitalMaureen A Smythe, John M Koerber, Joan C Mattson
Chest|May 21, 2008
The financial impact of heparin-induced thrombocytopeniaMaureen A Smythe, John M Koerber, Maureen Fitzgerald, et al.
The Annals of Pharmacotherapy|August 29, 2014
Implications of heparin-induced thrombocytopenia overdiagnosisMaureen A Smythe, John M Koerber, Lisa L Forsyth, et al.
The Annals of Pharmacotherapy|December 14, 2004
Effect of lepirudin on the international normalized ratioJennifer L Stephens, John M Koerber, Joan C Mattson, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
A comparison of lepirudin and argatroban outcomesMaureen A Smythe, Jennifer L Stephens, John M Koerber, et al.
Hospital Pharmacy|March 7, 2024
Hospital Acquired Venous Thromboembolism: A Preventability AssessmentMaureen A Smythe, John M Koerber, Amanda Roberts, et al.
Hospital Practice (1995)|July 31, 2018
Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomesSarah Eisho, Nouran M Salem, Janet L Hoffman, et al.
The Annals of Pharmacotherapy|May 30, 2003
Comparing methods of establishing the aPTT therapeutic range of heparinClaire I Liepman, John M Koerber, Joan C Mattson, et al.
Pageof 2